Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).
作者信息
Wick Wolfgang, Weller Michael
出版信息
Neuro Oncol. 2011 May;13(5):559-60; author reply 561-2. doi: 10.1093/neuonc/nor046.
Abstract
摘要
相似文献
1
Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).靶向转化生长因子-β的曲贝替定：当过程并非回报时，参考博格达恩等人（《神经肿瘤学》2011年；13:132 - 142）。
Neuro Oncol. 2011 May;13(5):559-60; author reply 561-2. doi: 10.1093/neuonc/nor046.
2
Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).对流增强递送转化生长因子-β2抑制剂曲贝替定治疗复发性高级别胶质瘤：疗效是真实的还是假象的？，参考博格达恩等人（《神经肿瘤学》2011年；13:132 - 142）。
Neuro Oncol. 2011 May;13(5):558-9; author reply 561-2. doi: 10.1093/neuonc/nor048.
3
4
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.针对 TGF-β2 抑制剂 trabedersen 治疗高级别脑胶质瘤的靶向治疗：一项随机对照的 2b 期研究结果。
Neuro Oncol. 2011 Jan;13(1):132-42. doi: 10.1093/neuonc/noq142. Epub 2010 Oct 27.
5
Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.用 TGF-β2 反义寡核苷酸治疗恶性神经胶质瘤。
Expert Rev Anticancer Ther. 2009 Nov;9(11):1663-74. doi: 10.1586/era.09.138.
6
TGF-β2 signaling in high-grade gliomas.TGF-β2 信号在高级别胶质瘤中的作用。
Curr Pharm Biotechnol. 2011 Dec;12(12):2150-7. doi: 10.2174/138920111798808347.
7
The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2.靶向抑制 TGF-β2 的反义寡核苷酸 trabedersen（AP 12009）。
Curr Pharm Biotechnol. 2011 Dec;12(12):2203-13. doi: 10.2174/138920111798808266.
8
Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.用 trabectedin（AP 12009）沉默转化生长因子-β2 基因治疗胰腺癌。
Cancer Sci. 2011 Jun;102(6):1193-200. doi: 10.1111/j.1349-7006.2011.01917.x. Epub 2011 Mar 30.
9
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.AP 12009对复发性恶性胶质瘤中转化生长因子-β2的抑制作用：从临床前研究到I/II期研究
Oligonucleotides. 2007 Summer;17(2):201-12. doi: 10.1089/oli.2006.0053.
10
Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.用于治疗恶性胶质瘤的缓释聚合物系统间质化疗
Recent Results Cancer Res. 1994;135:149-54. doi: 10.1007/978-3-642-85039-4_15.
引用本文的文献
1
Artificial intelligence-driven discovery of YH395A: A novel TGFβR1 inhibitor with potent anti-tumor activity against triple-negative breast cancer.人工智能驱动发现YH395A：一种对三阴性乳腺癌具有强效抗肿瘤活性的新型转化生长因子β受体1（TGFβR1）抑制剂。
Cell Commun Signal. 2025 Jul 8;23(1):326. doi: 10.1186/s12964-025-02337-2.
2
Recent advances in therapeutic use of transforming growth factor-beta inhibitors in cancer and fibrosis.转化生长因子-β抑制剂在癌症和纤维化治疗应用中的最新进展。
Front Oncol. 2025 Apr 25;15:1489701. doi: 10.3389/fonc.2025.1489701. eCollection 2025.
3
TGF-β-Based Therapies for Treating Ocular Surface Disorders.基于 TGF-β 的眼表疾病治疗方法。
Cells. 2024 Jun 26;13(13):1105. doi: 10.3390/cells13131105.
4
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.靶向转化生长因子-β异构体用于癌症治疗干预的进展与挑战：基于机制的视角
Pharmaceuticals (Basel). 2024 Apr 20;17(4):533. doi: 10.3390/ph17040533.
5
Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.寡核苷酸疗法作为治疗恶性脑肿瘤的新药类：靶向 mRNAs、调控 RNA、突变、联合用药及其他。
Neurotherapeutics. 2019 Apr;16(2):319-347. doi: 10.1007/s13311-018-00702-3.
6
Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors.转化生长因子-β异构体在 GBM 肿瘤中的差异表达及其临床意义。
Int J Mol Sci. 2018 Apr 8;19(4):1113. doi: 10.3390/ijms19041113.
7
Targeting TGF-β Signaling for Therapeutic Gain.靶向 TGF-β 信号转导以获得治疗增益。
Cold Spring Harb Perspect Biol. 2017 Oct 3;9(10):a022301. doi: 10.1101/cshperspect.a022301.
8
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.恶性胶质瘤的免疫抑制机制：与非中枢神经系统部位的相似之处
Front Oncol. 2015 Jul 6;5:153. doi: 10.3389/fonc.2015.00153. eCollection 2015.
9
Transforming growth factor-β pathway activity in glioblastoma.胶质母细胞瘤中转化生长因子-β信号通路活性
Oncotarget. 2015 Mar 20;6(8):5963-77. doi: 10.18632/oncotarget.3467.
10
Microenvironmental clues for glioma immunotherapy.胶质瘤免疫治疗的微环境线索。
Curr Neurol Neurosci Rep. 2014 Apr;14(4):440. doi: 10.1007/s11910-014-0440-1.
本文引用的文献
1
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.针对 TGF-β2 抑制剂 trabedersen 治疗高级别脑胶质瘤的靶向治疗：一项随机对照的 2b 期研究结果。
Neuro Oncol. 2011 Jan;13(1):132-42. doi: 10.1093/neuonc/noq142. Epub 2010 Oct 27.
2
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.替莫唑胺对比洛莫司汀、司莫司汀和长春新碱治疗复发性高级别胶质瘤。
J Clin Oncol. 2010 Oct 20;28(30):4601-8. doi: 10.1200/JCO.2009.27.1932. Epub 2010 Sep 20.
3
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.高级别胶质瘤更新后的反应评估标准：神经肿瘤学工作组的反应评估。
J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.
4
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.NOA-04 间变性胶质瘤序贯放化疗（采用丙卡巴肼、洛莫司汀和长春新碱或替莫唑胺）的随机 III 期试验
J Clin Oncol. 2009 Dec 10;27(35):5874-80. doi: 10.1200/JCO.2009.23.6497. Epub 2009 Nov 9.
5
TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.转化生长因子-β通过诱导白血病抑制因子来增加人胶质母细胞瘤中胶质瘤起始细胞的自我更新能力。
Cancer Cell. 2009 Apr 7;15(4):315-27. doi: 10.1016/j.ccr.2009.02.011.
6
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.在SMA - 560胶质瘤模型中，抑制转化生长因子-β信号通路可恢复免疫监视。
Neuro Oncol. 2007 Jul;9(3):259-70. doi: 10.1215/15228517-2007-010. Epub 2007 May 23.
7
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.转化生长因子-β RI抑制对艾克大鼠的肿瘤特异性疗效。
Clin Cancer Res. 2007 May 15;13(10):3087-99. doi: 10.1158/1078-0432.CCR-06-1811.
8
Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.转化生长因子-β：胶质母细胞瘤未来治疗的分子靶点。
Curr Pharm Des. 2006;12(3):341-9. doi: 10.2174/138161206775201901.
9
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.SD-208是一种新型的转化生长因子β受体I激酶抑制剂，在体外和体内均能抑制小鼠和人类胶质瘤细胞的生长与侵袭，并增强其免疫原性。
Cancer Res. 2004 Nov 1;64(21):7954-61. doi: 10.1158/0008-5472.CAN-04-1013.
10
RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.靶向转化生长因子-β的RNA干扰增强NKG2D介导的抗胶质瘤免疫反应，抑制胶质瘤细胞迁移和侵袭，并消除体内致瘤性。
Cancer Res. 2004 Oct 15;64(20):7596-603. doi: 10.1158/0008-5472.CAN-04-1627.
Zotero 插件